Drug Profile
Murlentamab - GamaMabs Pharma
Alternative Names: 3C23K; Anti-AMHR2 monoclonal antibody - GamaMabs; Anti-MISRII humanised monoclonal antibody 3C23K; Anti-mullerian human receptor-II monoclonal antibody - GamaMabs; GM-102; Humanised monoclonal antibody 3C23KLatest Information Update: 28 Apr 2024
Price :
$50
*
At a glance
- Originator LFB Biotechnologies
- Developer GamaMabs Pharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Anti-Mullerian hormone receptor antagonists; Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- No development reported Gynaecological cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Gynaecological-cancer(Late-stage disease, Second-line therapy or greater) in Belgium (Parenteral)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Gynaecological-cancer(Late-stage disease, Second-line therapy or greater) in France (Parenteral)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Gynaecological-cancer(Late-stage disease, Second-line therapy or greater) in United Kingdom (Parenteral)